Selskabets formål er at drive virksomhed indenfor bioteknologi og anden dermed i forbindelse stående virksomhed, herunder udvikling, produktion og salg af diagnostiske kit samt eje datterselskaber i forbindelse hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 426.3 mio. | 54.5 mio. | 426.1 mio. | 71.2 mio. | 179 | |
CVR: 30511271
Compared to 50.000 companies in Ikke-finansielle holdingselskaber
Comparison is based on industry median values
The financial health of NORDIC BIOSCIENCE HOLDING A/S appears to be declining, with a significant drop in revenue from 527.4 million DKK in 2024 to 426.3 million DKK in 2025, alongside a decrease in profit from 170.8 million DKK to 54.5 million DKK. Equity has also decreased from 230.9 million DKK in 2024 to 71.2 million DKK in 2025, indicating potential concerns regarding financial stability. The company's profit margins have fluctuated, with notable profits in previous years, but recent trends suggest a need for strategic adjustments to improve profitability and equity position. Overall, while the company has a presence in the non-financial holding sector, its recent financial trajectory raises questions about its competitive standing and operational efficiency.
AI-generated summary
Companies in the same industry and area
companydata.dk